Bupropion can serve as a discriminative stimulus (SD) in an operant drug discrimination task, and a variety of stimulants substitute for the bupropion SD. There are no reports, however, of bupropion functioning as a Pavlovian occasion setter (i.e., feature positive modulator). The present experiment seeks to fill this gap in the literature by training bupropion in rats as a feature positive modulator that disambiguates when a light will be paired with sucrose. Specifically, on bupropion (10 mg/kg IP) sessions, offset of 15-sec cue lights were followed by brief delivery of liquid sucrose; saline sessions were similar except no sucrose was available. Rats readily acquired the discrimination with more conditioned responding to the light on bup...
Cocaine addiction is associated with an extremely high rate of relapse, the resumption of drug takin...
bS Supporting Information ABSTRACT: Toward development of smoking cessation aids superior to bupropi...
Rationale — The cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (SR 141716) has been ...
Bupropion reduces the subjective effects and cue-induced craving for methamphetamine in humans. Give...
smoking cessation aid has not been fully elucidated, studies have found that bupropion and nicotine ...
Bupropion is a promising candidate medication for methamphetamine use disorder. As such, we used a p...
Bupropion is an atypical antidepressant that increases long-term quit rates of tobacco smokers. A be...
The present experiments examined whether a nicotine state could set the occasion for a pairing betwe...
Rationale: In Pavlovian conditioning research, nicotine is typically conceptualized as the unconditi...
Besides the antidepressant activity of bupropion (BP), preclinical studies in rodents provide eviden...
Bupropion is an effective anti-smoking agent in humans, but the behavioral mechanisms mediating this...
Objective(s)Bupropion is an atypical antidepressant that is widely used in smoke cessation under FDA...
People diagnosed with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk to st...
Nicotine and varenicline (Chantix®; the leading non-nicotine cessation pharmacotherapy) can come to ...
Recent research examining Pavlovian appetitive conditioning has extended the associative properties ...
Cocaine addiction is associated with an extremely high rate of relapse, the resumption of drug takin...
bS Supporting Information ABSTRACT: Toward development of smoking cessation aids superior to bupropi...
Rationale — The cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (SR 141716) has been ...
Bupropion reduces the subjective effects and cue-induced craving for methamphetamine in humans. Give...
smoking cessation aid has not been fully elucidated, studies have found that bupropion and nicotine ...
Bupropion is a promising candidate medication for methamphetamine use disorder. As such, we used a p...
Bupropion is an atypical antidepressant that increases long-term quit rates of tobacco smokers. A be...
The present experiments examined whether a nicotine state could set the occasion for a pairing betwe...
Rationale: In Pavlovian conditioning research, nicotine is typically conceptualized as the unconditi...
Besides the antidepressant activity of bupropion (BP), preclinical studies in rodents provide eviden...
Bupropion is an effective anti-smoking agent in humans, but the behavioral mechanisms mediating this...
Objective(s)Bupropion is an atypical antidepressant that is widely used in smoke cessation under FDA...
People diagnosed with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk to st...
Nicotine and varenicline (Chantix®; the leading non-nicotine cessation pharmacotherapy) can come to ...
Recent research examining Pavlovian appetitive conditioning has extended the associative properties ...
Cocaine addiction is associated with an extremely high rate of relapse, the resumption of drug takin...
bS Supporting Information ABSTRACT: Toward development of smoking cessation aids superior to bupropi...
Rationale — The cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (SR 141716) has been ...